Ascendis Pharma A/S (BSP:A1SN34)
R$ 48.42 0 (0%) Market Cap: 2.77 Bil Enterprise Value: 4.70 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 59/100

Q4 2022 Ascendis Pharma A/S Earnings Call Transcript

Feb 16, 2023 / 09:30PM GMT
Release Date Price: R$38.4 (-5.14%)
Operator

Good day, and thank you for standing by. Welcome to the Ascendis Pharma Full Year 2022 Financial Results Conference Call. (Operator Instructions)

I would like to turn the call over to now for your speaker for today. Tim Lee, Senior Director of Investor Relations. Please go ahead. The floor is yours.

Timothy J. Lee;S;Senior Director of IR
Ascendis Pharma A

/-

Thank you, operator, and thank you, everyone, for joining our full year 2022 financial results conference call. I'm Tim Lee, Senior Director of Investor Relations of Ascendis Pharma. Joining me on the call today is Jan Mikkelsen, President and Chief Executive Officer; Scott Smith, Executive Vice President and Chief Financial Officer; Dr. Stina Singel, Executive Vice President, Head of Clinical Development Oncology; and Joe Kelly, Senior Vice President, Head of U.S. Commercial, Endocrinology. Before we begin, I'd like to remind you that this conference call will contain forward-looking statements that are intended to be covered under the safe harbor provided by the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot